Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Summary

This phase I trial is studying the side effects and best dose of bevacizumab in treating young patients with refractory solid tumors. Monoclonal antibodies, such as bevacizumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

Timeline

Start

2003-12

Primary completion

2005-10

Completion

—

Drugs

Indications